Use of proteasome inhibitors

Current Protocols in Immunology

Volumn 2015, Issue , 2015, Pages 9.10.1-9.10.9

  Downey, Sondra L ^a   Florea, Bogdan I ^b   Overkleeft, Herman S ^b   Kisselev, Alexei F ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NETHERLANDS PROTEOMICS CENTRE   (Netherlands)

Author keywords

Boronates; Peptide aldehydes; Peptide epoxyketones; Proteosome inhibitors

Indexed keywords

ALDEHYDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CARFILZOMIB; EPOXOMICIN; LACTACYSTIN BETA LACTONE; OPROZOMIB; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN;

ANIMAL CELL CULTURE; APOPTOSIS; ARTICLE; CONCENTRATION (PARAMETERS); DRUG EXPOSURE; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; INHIBITION KINETICS; MAMMAL CELL; PRIORITY JOURNAL; STRUCTURE ANALYSIS; ANIMAL; CHEMISTRY; CLASSIFICATION; DRUG EFFECTS; METABOLISM; PROTEIN DEGRADATION; RESEARCH; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEOLYSIS; RESEARCH; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 84949255415     PISSN: 19343671     EISSN: 1934368X     Source Type: Journal    
DOI: 10.1002/0471142735.im0910s109     Document Type: Article

References (40)

1. Adams, J., Behnke, M., Chen, S., Cruickshank, A.A., Dick, L.R., Grenier, L., Klunder, J.M., Ma, Y.T., Plamondon, L., and Stein, R.L. 1998. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8:333-338.
2. Anchoori, R.K., Karanam, B., Peng, S., Wang, J.W., Jiang, R., Tanno, T., Orlowski, R.Z., Matsui, W., Zhao, M., Rudek, M.A., Hung, C.F., Chen, X., Walters, K.J., and Roden, R.B. 2013. A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Can. Cell 24:791-805.
3. Arastu-Kapur, S., Anderl, J.L., Kraus, M., Parlati, F., Shenk, K.D., Lee, S.J., Muchamuel, T., Bennett, M.K., Driessen, C., Ball, A.J., and Kirk, C.J. 2011. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: A link to clinical adverse events. Clin. Cancer Res. 17:2734-2743.
4. Arendt, C.S. and Hochstrasser, M. 1997. Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for activesite formation. Proc. Natl. Acad. Sci. 94:7156-7161.
5. Bachovchin, D.A., Koblan, L.W., Wu, W., Liu, Y., Li, Y., Zhao, P., Woznica, I., Shu, Y., Lai, J.H., Poplawski, S.E., Kiritsy, C.P., Healey, S.E., Di-Mare, M., Sanford, D.G., Munford, R.S., Bachovchin, W.W., and Golub, T.R. 2014. A highthroughput, multiplexed assay for superfamilywide profiling of enzyme activity. Nat. Chem. Biol. 10:656-663.
6. Britton, M., Lucas, M.M., Downey, S.L., Screen, M., Pletnev, A.A., Verdoes, M., Tokhunts, R.A., Amir, O., Goddard, A.L., Pelphrey, P.M., Wright, D.L., Overkleeft, H.S., and Kisselev, A.F. 2009. Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. Chem. Biol. 16:1278-1289.
7. Chen, P. and Hochstrasser, M. 1996. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell 86:961-972.
8. Chondrogianni, N., Stratford, F.L., Trougakos, I.P., Friguet, B., Rivett, A.J., and Gonos, E.S. 2003. Central role of the proteasome in senescence and survival of human fibroblasts: Induction of a senescence-like phenotype upon its inhibition and resistance to stress upon its activation. J. Biol. Chem. 278:28026-28037.
9. Demo, S.D., Kirk, C.J., Aujay, M.A., Buchholz, T.J., Dajee, M., Ho, M.N., Jiang, J., Laidig, G.J., Lewis, E.R., Parlati, F., Shenk, K.D., Smyth, M.S., Sun, C.M., Vallone, M.K., Woo, T.M., Molineaux, C.J., and Bennett, M.K. 2007. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 67:6383-6391.
10. Dick, L.R., Cruikshank, A.A., Destree, A.T., Grenier, L., McCormack, T.A., Melandri, F.D., Nunes, S.L., Palombella, V.J., Parent, L.A., Plamondon, L., and Stein, R.L. 1997. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J. Biol. Chem. 272:182-188.
11. Fenteany, G., Standaert, R.F., Lane, W.S., Choi, S., Corey, E.J., and Schreiber, S.L. 1995. Inhibition of proteasome activities and subunitspecific amino-terminal threonine modification by lactacystin. Science 268:726-731.
12. Figueiredo-Pereira, M.E., Berg, K.A., and Wilk, S. 1994. A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell. J. Neurochem. 63:1578-1581.
13. Finley, D. 2009. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem 78:477-513.
14. Geier, E., Pfeifer, G., Wilm, M., Lucchiari-Hartz, M., Baumeister, W., Eichmann, K., and Niedermann, G. 1999. A giant protease with potential to substitute for some functions of the proteasome. Science 283:978-981.
15. Granot, Z., Kobiler, O., Melamed-Book, N., Eimerl, S., Bahat, A., Lu, B., Braun, S., Maurizi, M.R., Suzuki, C.K., Oppenheim, A.B., and Orly, J. 2007. Turnover of mitochondrial steroidogenic acute regulatory (StAR) protein by Lon protease: The unexpected effect of proteasome inhibitors. Mol. Endocrinol. 21:2164-2177.
16. Groll, M. and Huber, R. 2004. Inhibitors of the eukaryotic 20S proteasome core particle: A structural approach. Biochim. Biophys. Acta 1695:33-44.
17. Groll, M., Koguchi, Y., Huber, R., and Kohno, J. 2001. Crystal structure of the 20S proteasome:TMC-95A complex: A noncovalent proteasome inhibitor. J. Mol. Biol. 311:543-548.
18. Groll, M., Kim, K.B., Kairies, N., Huber, R., and Crews, C.M. 2000. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of α',β'-epoxyketone proteasome inhibitors. J. Am. Chem. Soc. 122:1237-1238.
19. Gronostajski, R.M., Pardee, A.B., and Goldberg, A.L. 1985. The ATP dependence of the degradation of short- and long-lived proteins in growing fibroblasts. J. Biol. Chem. 260:3344-3349.
20. Heinemeyer, W., Fischer, M., Krimmer, T., Stachon, U., and Wolf, D.H. 1997. The active sites of the eukaryotic 20S proteasome and their involvement in subunit precursor processing. J. Biol. Chem 272:25200-25209.
21. Ito, H., Watanabe, M., Kim, Y.T., and Takahashi, K. 2009. Inhibition of rat liver cathepsins B and L by the peptide aldehyde benzyloxycarbonylleucyl-leucyl-leucinal and its analogues. J. Enzyme. Inhib. Med. Chem. 24:279-286.
22. Kisselev, A.F. and Goldberg, A.L. 2001. Proteasome inhibitors: From research tools to drug candidates. Chem. Biol. 8:739-758.
23. Kisselev, A.F., Callard, A., and Goldberg, A.L. 2006. Importance of different active sites in protein breakdown by 26S proteasomes and the efficacy of proteasome inhibitors varies with the protein substrate. J. Biol. Chem. 281:8583-8590.
24. Kisselev, A.F., van der Linden, W.A., and Overkleeft, H.S. 2012. Proteasome inhibitors: An expanding army attacking a unique target. Chem. Biol. 19:99-115.
25. Kulathu, Y. and Komander, D. 2012. Atypical ubiquitylation-the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat. Rev. Mol. Cell Biol. 13:508-523.
26. Lee, B.H., Lee, M.J., Park, S., Oh, D.C., Elsasser, S., Chen, P.C., Gartner, C., Dimova, N., Hanna, J., Gygi, S.P., Wilson, S.M., King, R.W., and Finley, D. 2010. Enhancement of proteasome activity by a small-molecule inhibitor ofUSP14. Nature 467:179-184.
27. Lim, H.S., Archer, C.T., and Kodadek, T. 2007. Identification of a peptoid inhibitor of the proteasome 19S regulatory particle. J. Am. Chem. Soc. 129:7750-7751.
28. Mirabella, A.C., Pletnev, A.A., Downey, S.L., Florea, B.I., Shabaneh, T.B., Britton, M., Verdoes, M., Filippov, D.V., Overkleeft, H.S., and Kisselev, A.F. 2011. Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem. Biol. 18:608-618.
29. Molineaux, S.M. 2012. Targeting proteasomal protein degradation in cancer. Clin. Cancer Res. 18:15-20.
30. Moravec, R.A., O'Brien, M.A., Daily, W.J., Scurria, M.A., Bernad, L., and Riss, T.L. 2009. Cellbased bioluminescent assays for all three proteasome activities in a homogeneous format. Anal. Biochem. 387:294-302.
31. Ostrowska, H., Wojcik, C., Omura, S., and Worowski, K. 1997. Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme. Biochem Biophys. Res. Commun. 234:729-732.
32. Palombella, V.J., Rando, O.J., Goldberg, A.L., and Maniatis, T. 1994. The ubiquitin-proteasome pathway is required for processing the NFkappa-B1 precursor protein and the activation of NF-kappa-B. Cell 78:773-785.
33. Potts, B.C., Albitar, M.C., Anderson, K.C., Baritaki, S., Berkers, C., Bonavida, B., Chandra, J., Chauchan, D., Cusacck, J.C., Fenical, W., Ghobrial, I.M., Groll, M., Jense, P.R., Lam, K.S., Llloyd, G.K., McBride, W., McConKey, D.J., Miller, C.P., Neuteboom, S.T.C., Oki, Y., Ovaa, H., Pajonk, F., Richardson, P.G., Roccaro, A.M., Sloss, C.M., Spear, A.M., Valashi, E., Younes, A., and Palladino, M.A. 2011. Marizomib, a proteasome inhibitor for all seasons: Preclinical profile and a framewrok for clinical trials. Curr. Can. Drug. Targets. 11:254-284.
34. Rock, K.L. and Goldberg, A.L. 1999. Degradation of cell proteins and generation of MHC class Ipresented peptides. Ann. Rev. Immunol. 17:739-779.
35. Rock, K.L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., and Goldberg, A.L. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class 1 molecules. Cell 78:761-771.
36. Shabaneh, T.B., Downey, S.L., Goddard, A.L., Screen, M., Lucas, M.M., Eastman, A., and Kisselev, A.F. 2013. Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PloS one 8:e56132.
37. Tsubuki, S., Saito, Y., Tomioka, M., Ito, H., and Kawashima, S. 1996. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J. Biochem. 119:572-576.
38. Verdoes, M., Willems, L.I., van der Linden, W.A., Duivenvoorden, B.A., van der Marel, G.A., Florea, B.I., Kisselev, A.F., and Overkleeft, H.S. 2010. A panel of subunit-selective activity-based proteasome probes. Org. Biomol. Chem.8:2719-2727.
39. Verdoes, M., Florea, B.I., Menendez-Benito, V., Witte, M.D., van der Linden, W.A., van den Nieuwendijk, A.M.C.H., Hofmann, T., Berkers, C., van Leeuwen, F.W.B., Groothuis, T.A., Leeuwenburgh, M.A., Ovaa, H., Neefjes, J., Filippov, D.V., van der Marel, G.A., Dantuma, N.P., and Overkleeft, H.S. 2006. A fluorescent broad spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem. Biol. 13:1217-1226.
40. Wilkins, O.M., Downey, S.L., Weyburne, E.S., Williams, D.A., Mirabella, A.C., Overkleeft, H.S., and Kisselev, A.F. 2014. Cell-line-specific high background in the Proteasome-Glo assay of proteasome trypsin-like activity. Anal. Biochem. 451:1-3.